PCM
HHS icon

Prelude Capital Management’s Harte-Hanks HHS Stock Holding History

Prelude Capital Management’s Portfolio HHS Stock Details HHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-70
Closed -$1K – 1698
2017
Q1 		$1K Buy
70
+20
+40% +$305 ﹤0.01% 1460
2016
Q4 		$1K Buy
+50
New +$758 ﹤0.01% 1498
2016
Q2 		– Sell
-2,740
Closed -$69K – 1633
2016
Q1 		$69K Buy
2,740
+90
+3% +$2.77K 0.01% 876
2015
Q4 		$86K Buy
2,650
+1,635
+161% +$61.2K 0.01% 866
2015
Q3 		$36K Sell
1,015
-170
-14% -$7.67K 0.01% 1136
2015
Q2 		$71K Buy
1,185
+70
+6% +$4.71K 0.01% 1023
2015
Q1 		$87K Sell
1,115
-1,055
-49% -$81.6K 0.01% 1070
2014
Q4 		$168K Buy
2,170
+610
+39% +$39.9K 0.02% 740
2014
Q3 		$99K Sell
1,560
-870
-36% -$59.1K 0.01% 1094
2014
Q2 		$175K Buy
+2,430
New +$188K 0.02% 797

Other funds holding HHS

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
VCA
VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Prelude Capital Management's HHS Position: Q2 2017 in Review

Prelude Capital Management sold out of Harte-Hanks (HHS) in Q2 2017, closing a stake of 70 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in HHS in Q2 2014 and held it in 10 quarters. The position peaked at $175K in Q2 2014. 63 funds tracked by Wall St. Rank hold HHS as of Q2 2017.

  • Prelude Capital Management reported no remaining Harte-Hanks position as of Q2 2017 after selling out during the quarter.
  • Prelude Capital Management sold 70 Harte-Hanks shares in Q2 2017, an estimated $1K.
  • Prelude Capital Management first reported a position in Harte-Hanks in Q2 2014 and held it in 10 quarters.
  • Prelude Capital Management's Harte-Hanks position peaked at $175K in Q2 2014.
  • 63 funds tracked by Wall St. Rank held Harte-Hanks as of Q2 2017.

Based on Prelude Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.